Stock Events

Evolus 

$12.02
33
-$0.05-0.41% Tuesday 20:00

Statistics

Day High
12.42
Day Low
12
52W High
15.43
52W Low
7.11
Volume
438,094
Avg. Volume
555,909
Mkt Cap
752.45M
P/E Ratio
-11.56
Dividend Yield
-
Dividend
-

Earnings

7MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.32
-0.24
-0.16
-0.08
Expected EPS
-0.1
Actual EPS
-0.08

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EOLS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck &
MRK
Mkt Cap323.59B
Merck & Co., through its acquisition of companies and products, competes in the aesthetics and dermatology space, potentially overlapping with Evolus's market.
GSK
GSK
Mkt Cap81.16B
GlaxoSmithKline, a large pharmaceutical company, has a diverse portfolio that includes products competing in the aesthetics space.
Pfizer
PFE
Mkt Cap163.88B
Pfizer, with its broad range of healthcare products, competes in various segments, including those that overlap with Evolus's interests.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie, after acquiring Allergan, directly competes with Evolus in the cosmetic injectable market, particularly with its Botox product.
SPDR SSgA Global Allocation
GAL
Mkt Cap228.82M
Galderma, a company specializing in dermatological treatments, offers a range of products that compete in the same space as Evolus's offerings.
Revolve
RVLV
Mkt Cap618.41M
Revolve, while primarily known for its fashion retail, has ventured into beauty and skincare products that could indirectly compete with Evolus.
Johnson & Johnson
JNJ
Mkt Cap360.71B
Johnson & Johnson, through its wide range of healthcare products, has interests in the dermatology and aesthetics market, competing with Evolus.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.57B
Teva Pharmaceutical Industries, with its generic and specialty medicines, competes in the broader pharmaceutical market, including areas relevant to Evolus.
Novartis
NVS
Mkt Cap244.62B
Novartis, a global healthcare company, has a diverse portfolio that includes dermatology and aesthetics, competing with Evolus in certain markets.

Analyst Ratings

22.6$Average Price Target
The highest estimate is $27.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Show more...
CEO
David Moatazedi
Employees
279
Country
US
ISIN
US30052C1071
WKN
000A2JDYX

Listings